Avalo Therapeutics (AVTX) closed at $6.93 on November 6, 2026, up 4.5% from the previous close, on volume of 912,809 shares (30-day average 2,175,961).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts | Position |
|---|---|---|---|---|---|
| 1 | Oct 23, 2026 | Straddle or Synthetic | 18-Dec-267.5 C : 7.5 P | 4,730 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
TipRanks (Fri, 6-Nov 9:07 AM ET)
Avalo Therapeutics: Neutral Amid Strong Cash Position and Significant Clinical Uncertainty
TipRanks (Fri, 6-Nov 9:01 AM ET)
Bank of America Securities Sticks to Their Buy Rating for Avalo Therapeutics (AVTX)
TipRanks (Fri, 6-Nov 7:58 AM ET)
Avalo Therapeutics Enters New $200 Million Stock Sales Agreement
TipRanks (Thu, 5-Nov 8:51 AM ET)
Avalo Therapeutics GAAP EPS of -$0.34 beats by $0.27
Seeking Alpha News (Thu, 5-Nov 7:43 AM ET)
Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Updates
Globe Newswire (Thu, 5-Nov 7:00 AM ET)
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Globe Newswire (Mon, 2-Nov 4:00 PM ET)
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Tue, 29-Sep 4:01 PM ET)
Globe Newswire (Wed, 23-Sep 7:00 AM ET)
Market Chameleon (Wed, 6-May 5:54 AM ET)
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
Avalo Therapeutics trades on the NASDAQ stock market under the symbol AVTX.
As of November 6, 2026, AVTX stock price climbed to $6.93 with 912,809 million shares trading.
AVTX has a beta of 1.56, meaning it tends to be more sensitive to market movements. AVTX has a correlation of 0.04 to the broad based SPY ETF.
AVTX has a market cap of $371.66 million. This is considered a Small Cap stock.
In the last 3 years, AVTX traded as high as $34.46 and as low as $3.39.
The top ETF exchange traded funds that AVTX belongs to (by Net Assets): VTI, XBI, IWM, VXF, VTWO.
AVTX has underperformed the market in the last year with a return of -55.1%, while the SPY ETF gained +10.8%. In the last 3 month period, AVTX fell short of the market, returning -62.9%, while SPY returned -4.1%. However, in the most recent 2 weeks AVTX has outperformed the stock market by returning 0.0%, while SPY returned -3.2%.
AVTX support price is $6.27 and resistance is $6.99 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVTX shares will trade within this expected range on the day.
